US FDA Advisory Committees Could Get Revamp With A Focus On Science Over Emotion
Executive Summary
CDER Director Cavazzoni also wants to loosen conflict of interest rules and improve technology for remote meetings. Given FDA’s approval of Aduhelm, her comments, made in a prerecorded interview for the BIO Digital annual meeting, may raise some eyebrows. Industry is also working on recommendations for the agency on the topic.
You may also be interested in...
Adcomm Member Survey Shows Continued Support For Virtual Meetings After Pandemic
Despite acknowledging that fully in-person meetings overall are better, survey respondents said they still want the flexibility that virtual attendance offers.
US FDA Advisory Committee Members Say Votes Should More Directly Affect Agency Decisions
Survey of advisory committee members finds many believe an overwhelmingly negative vote should prevent a product approval. Survey was prompted by FDA accelerated approval of Alzheimer’s disease treatment Aduhelm despite overwhelming committee rejection.
For US FDA, Modernizing Advisory Committees Includes How Meetings Are Scheduled
Agency officials are considering developing policies for when an advisory committee meeting is appropriate, in part because of the workload associated with them. Could fewer meetings result?